XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Basis of Presentation (Tables)
3 Months Ended
Mar. 31, 2023
Accounting Changes and Error Corrections [Abstract]  
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] summary of the adjustments as of and for the three months ended March 31, 2023 included in the Explanatory Note of this Form 10-Q/A.

 

 

 

For the three months ended March 31, 2023

 

Dollars in thousands, except per share data (unaudited)

 

As Reported

 

 

Adjustments

 

 

As Restated

 

Net interest income

 

$

27,359

 

 

$

(2,163

)

 (a)

$

25,196

 

Provision (benefit) for credit losses - loans

 

 

4,100

 

 

 

(5,210

)

 (b)

 

(1,110

)

Income from continuing operations before income tax expense

 

 

2,095

 

 

 

3,047

 

 

 

5,142

 

Income tax expense

 

 

491

 

 

 

681

 

 (d)

 

1,172

 

Net income from continuing operations

 

$

1,604

 

 

$

2,366

 

 

$

3,970

 

Basic and diluted earnings per common share from continuing operations

 

$

0.09

 

 

$

0.12

 

 

$

0.21

 

 

 

 

As of March 31, 2023

 

Dollars in thousands (unaudited)

 

As Reported

 

 

Adjustments

 

 

As Restated

 

Loans held for investment, net of deferred fees and costs

 

$

2,448,992

 

 

$

(4,197

)

 (e)

$

2,444,795

 

Allowance for credit losses

 

 

(29,974

)

 

 

(5,987

)

 (c)

 

(35,961

)

Accrued interest receivable

 

 

14,915

 

 

 

(790

)

 (e)

 

14,125

 

Deferred tax asset, net

 

 

9,605

 

 

 

3,123

 

 (d)

 

12,728

 

Other assets

 

 

21,264

 

 

 

(3,000

)

 (e)

 

18,264

 

Total assets

 

$

3,334,911

 

 

$

(10,851

)

 

$

3,324,060

 

Total stockholders' equity

 

$

257,586

 

 

$

(10,851

)

 

$

246,735

 

 

 

(a) - Attributable to $63.5 million of specialty finance loans reported as nonaccrual (as restated), previously reported as accruing as of March 31, 2023. See Note 4 for restated disclosures.

 

(b) - Attributable to adjustments to specific reserves for specialty finance loans. See Note 4 for restated disclosures.

 

(c) - Attributable to adjustments noted in (b) and for adjustments for the implementation of ASC 326. See Note 2 for restated disclosures.

 

(d) - Deferred income tax benefit of 22.35% on pre-tax adjustments.

 

(e) - Related to reversal of accrued interest receivable associated with (a), reversal of capitalized accrued interest previously reported in loans held for investment, and to reflect the application of cash received in the first quarter of 2023 as a reduction in loans held for investment previously reported as interest and fee income on loans.

 

For the convenience of the reader, this Form 10-Q/A sets forth the information in the original Form 10-Q filing in its entirety; however, only the following sections of the original Form 10-Q filing are revised in this Form 10-Q/A, solely as a result of and to reflect the restatement and conditions related to the restatement noted above.

Part I, Item 1

Financial Statements and Notes to Consolidated Financial Statements

Notes:

Note 1 - Organization and Basis of Presentation

 

Note 2 - Adoption of New Accounting Standard

 

Note 4 - Loans and ACL

 

Note 10 - Fair Value

 

Note 11 - Minimum Regulatory Capital Requirements

 

Note 13 - Earnings Per Share

 

Note 14 - Business Segments

 

Note 17 - Subsequent Events

Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operation

Item 4

Controls and Procedures

Except as it relates to the restatement described above with related disclosures and updated subsequent events disclosures, this Form 10-Q/A does not reflect events occurring after the date of the original Form 10-Q filing.